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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is character-
ized by persistent respiratory symptoms and airflow limitation 
due to airway and/or alveolar abnormalities usually caused by 
prolonged exposure to noxious particles or gases.1 Cigarette 
smoking is the most common cause of COPD; however, envi-
ronmental factors, such as polluted air, second-hand smoke, or 
biomass smoke, could also cause COPD. In addition, genetic 
factors or suboptimal lung growth in childhood may be associ-
ated with the development of COPD (Fig. 1).2 Currently, COPD 
is the fourth leading cause of deaths worldwide, and by 2020, it 
is expected to be the third leading cause of deaths worldwide.1 
Approximately three million people died of COPD in 2015, ac-
counting for 5% of all deaths worldwide in that year.3 Due to 
the high prevalence and chronicity of COPD, it has been a glob-
al burden for many years, and the mechanisms of its develop-
ment remain unidentified. Intriguingly, the incidence of COPD 
becomes higher with aging, and peak incidence is observed in 
patients aged 65–74 years.4,5 Therefore, aging is considered a 
critical factor in the development of COPD.6 It has been pro-
posed that accelerated premature aging of the lungs may be the 
mechanism of COPD development.7 Once a patient is suspect-
ed as having COPD, the diagnosis is confirmed based on spi-
rometry results. For diagnosis of COPD, patients should have 
irreversible airflow limitation, which is defined by post-bron-
chodilator forced expired volume in 1 second (FEV1)/forced vi-
tal capacity (FVC) ratio of <0.70 according to the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) guidelines.8 
It is well documented that lung function typically declines with 
aging. Specifically, FEV1 decreases, and aging lungs, just like 
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COPD-affected lungs, often have FEV1/FVC ratio <0.70 and 
increased residual volume.9 This is because the physiology of 
aging lungs and COPD-affected lungs are similar, showing de-
creased elastic recoil of the lungs, stiffened chest wall, and altered 
gas exchange.6 In addition, similarly to COPD-affected lungs, 
aging lungs have decreased mucociliary clearance, compro-
mised vascular regulation, and alveolar enlargement.10 How-
ever, alveolar enlargement in aging lungs, so-called “senile em-
physema,” differs from that in COPD in terms of the lack of 
alveolar wall destruction and inflammation.9 It has been sug-
gested that the main driving force for COPD development 
could differ among individuals. For instance, suboptimal lung 
growth in childhood has also been shown to play an important 
role in causing COPD in some individuals.11 Taken together, 
although premature lung aging may not be a pathogenic mech-
anism in all COPD patients, many aspects of aging lungs and 
COPD-affected lungs are similar, implying that the mechanisms 
of aging may contribute to the development of COPD. In this 
study, based on our literature review, we propose that immu-
nosenescence, which is the gradual deterioration of the im-
mune system brought on by natural age advancement, is the 
key pathogenetic mechanism of COPD. 
COPD AS A CHRONIC INFLAMMATORY 
DISORDER
COPD is a chronic inflammatory disease induced by repeated 
exposure to respiratory irritants, mostly cigarette smoke, and 
inflammation in COPD-affected lungs continues to be observed 
even after stopping smoking.12 Normal immune responses dur-
ing inflammatory processes are expected to prevent lungs from 
further injury or infection; however, chronic inflammation in 
COPD-affected lungs is associated with abnormal immune 
responses leading to increased tissue damage, resulting in re-
modeling of the lung.12 Inflammation in COPD is predomi-
nantly driven by type 1 immunity and type 3 immunity.13 Both 
innate and adaptive immune systems are involved in the de-
velopment of chronic inflammation leading to COPD. The 
role of innate immunity in COPD pathogenesis has been ex-
tensively studied recently in terms of the induction and acute 
exacerbation of the disease.11,14 Interleukin (IL) 1-like cyto-
kines are reportedly elevated in the lungs of COPD patients, 
implying the role of an inflammasome in the pathogenesis of 
COPD.11,14 The inflammasome is a multiprotein intracellular 
complex that activates proinflammatory caspases, such as cas-
pase 1, leading to the cleavage of proinflammatory cytokines 
and production of active IL-1β and IL-18 in response to patho-
genic microorganisms and sterile stressors.11,14 To activate the 
inflammasome, innate immune cells should recognize patho-
gen-associated molecular patterns (PAMPs) of microbial 
pathogens or damage-associated molecular patterns (DAMPs) 
of sterile stressors that are categorized based on their subcellu-
lar origin (e.g., cytoplasm, endoplasmic reticulum, nucleus, and 
mitochondria). This recognition of PAMP or DAMP is achieved 
through several families of pattern recognition receptors 
(PRRs) expressed in innate immune cells.11,14 The PRRs include 
Toll-like receptors (TLRs), nucleotide-binding domain leu-
cine-rich repeat-containing receptors (NLRs), C-type lectin re-
ceptors, and RIG-I-like receptors.11,14 In the lungs, TLRs are ex-
pressed on various cells, including alveolar macrophages, 
lymphocytes, dendritic cells, and bronchial epithelial cells.11,14 
Among different TLRs, TLR4 reportedly plays an important 
role in murine models of COPD.15-17 TLRs recognize molecular 
patterns on the cell surface of a microbial pathogen, whereas 
NLRs identify molecular patterns in the cytosol of the host 
cell.18 It has been shown that the DAMPs generated by ciga-
rette smoke-induced death of airway epithelial cells or the 
PAMPs induced by microbial antigens activate the NLR family 
pyrin domain containing 3 (NLRP3) inflammasome, leading 
to the release of IL-1β with subsequent neutrophilic inflamma-
tion in the lungs of COPD patients.19,20 However, the role of the 
inflammasome in COPD development has been challenged 
recently. One study reported that, although innate immunity 
reportedly correlates with disease progression in COPD pa-
tients, the NLRP3 inflammasome is not activated in patients 
with stable COPD,21 thus, the exact roles of innate immunity, 
including that of the inflammasome, in COPD pathogenesis re-
main unclear. Several studies have reported on adaptive im-
mune responses in the lungs of COPD patients. Active partici-
pation of cytotoxic CD8+ T cells, T helper 1, and 17 CD4+ cells 
and B-cell response leading to the production of antibodies 
have been reported in COPD-affected lungs.22 Upon activa-
tion, CD8+ T cells release proteolytic enzymes, such as perfo-
rin or granzymes, which cause cell death of structural cells by 
apoptosis or necrosis.22 Th1 cells secrete interferon gamma and 
Th17 releases IL-17, thus leading to increased inflammation at 
the site of injury in response to cigarette exposure.23,24 In addi-
tion, smokers with COPD have significantly fewer T-regulatory 
cells in the lungs; this may contribute to the perpetuation of 
inflammation and the induction of autoimmunity. The devel-
opment of autoimmunity has been mostly reported in patients 
with severe COPD.25 Further, B cells are also increased in large 
Chronic repeated exposure
• Cigarette smoke
• Biomass smoke
• Second hand smoke
• Air pollution
Host factors
• Genetic susceptibility
• Suboptimal lung growth
• Premature lung aging Normal lung COPD lung
Bronchitis
Emphysema
Fig. 1. Causes and risk factors for COPD. Besides exposure to noxious 
particles or gases, host factors determine the susceptibility of individu-
als to develop COPD. COPD, chronic obstructive pulmonary disease.
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airways, and peribronchial lymphoid follicles are often ob-
served, which are due to lymphoid neogenesis in COPD-af-
fected lungs.26 Taken together, it is very likely that the interac-
tion between innate and adaptive immune cells may 
orchestrate the onset, progression, and severity of lower airway 
inflammation in COPD.21
IMMUNOSENESCENCE 
Given that COPD, a chronic inflammatory lung disease, is prob-
ably caused by accelerated lung aging, the changes in immune 
systems with aging may be associated with COPD pathogene-
sis. The immune system also undergoes an aging process 
termed immunosenescence. Both innate immunity and adap-
tive immunity are affected by aging.27 Aging innate immune 
cells, such as neutrophils, macrophages, dendritic cells, and 
natural killer cells, undergo functional decline in phagocytosis, 
chemotaxis, their ability to secrete inflammatory cytokine, an-
tigen-presenting capacity, and bactericidal ability.28-31 Declin-
ing function of innate immune cells with aging also contrib-
utes to the dysregulation of the adaptive immune system via 
molecular cross-talk.32 The decline in cell-mediated immunity 
forms a part of the aging immune profile, which is primarily 
characterized by reduced thymic output leading to reduced T-
cell repertoire and increased oligoclonal expansion of memo-
ry cells.33 In other words, reduced responsiveness to new anti-
gen load, owing to the reduced naïve to memory cell ratio and 
expansion of mature cell clones, characterizes immunosenes-
cence of cell-mediated immunity.34 Further, aging is also as-
sociated with shifts from Th1 cytokine profile to Th2 cytokine 
profile in response to immune stimulation. The overproduc-
tion of Th2 cytokines in this setting may augment B-cell-medi-
ated autoimmune disorders in older adults.35 Humoral immune 
function also changes significantly with aging; these changes 
include decreased antibody responses and diminished pro-
duction of high-affinity antibodies related to defective surface 
immunoglobulin/B-cell receptor affinity, decreased signaling, 
and reduced B-cell proliferation.36 There is also a loss of naïve 
B-cells and an increase in memory cells with age,37 resulting in 
a reduced ability to respond to new antigens.38 Overall, the im-
munosenescence of adaptive immunity results from the deple-
tion of the reservoir of naïve cells over time as a result of repeated 
exposure to pathogens and their conversion to memory cells.33
INFLAMMAGING  
(CHRONIC INFLAMMATION)
Immunosenescence leads not only to impaired immune re-
sponses but also to low-grade, chronic, systemic inflammation, 
which is described as inflammaging.39 Inflammaging is char-
acterized by elevated proinflammatory cytokines, such as IL-1, 
IL-6, and tumor necrosis factor (TNF)-α.40 Inflammaging is 
believed to be a cumulative result of lifetime exposure to anti-
genic load from infections, as well as exposure to noninfec-
tious antigens.41 Key genes that are known to regulate inflam-
maging include the insulin-like growth factor (IGF-1) signaling 
pathway, target of rapamycin (TOR), and AMP-activated pro-
tein kinase (AMPK).42 Not surprisingly, inflammaging has 
been proposed as one of the contributors to the development 
of most age-related disorders and as a common biological fac-
tor responsible for the decline and onset of diseases in older 
adults.43,44 Many factors are likely involved in inflammaging. 
First, intrinsic dysregulation of immune cells simply may be a 
cause of inflammaging. Regarding the innate immune system, 
monocytes and macrophages are suggested to contribute to 
inflammaging significantly by the active generation of inflam-
matory cytokines.29 In addition, T cell-mediated immunity 
can induce inflammaging by changing their phenotype into a 
more proinflammatory phenotype in a manner dependent on 
previous exposure, reactivation of antigenic challenges, and 
exhaustion of T-cell repertoire.29 The CD8+ T cell population is 
thought to be a bigger contributor in this regard than the CD4+ 
population.45 Second, senescent cells can produce proinflam-
matory mediators and proteases, which are collectively termed 
as senescence-associated secretory phenotypes (SASPs).46 
SASPs may activate inflammatory responses by recruiting im-
mune cells possibly to cause inflammaging.47 Third, age-relat-
ed changes in adiposity and hormones (e.g., estrogen) report-
edly cause inflammation. Proinflammatory cytokines and free 
fatty acids secreted from inflamed adipose tissue can activate 
inflammation, which may be a part of inflammaging.48,49 
Fourth, age-associated changes in gut microbe concentrations 
may foster an imbalance in vivo that affects inflammaging.50 
Fifth, increased cell death or damage to cellular components 
induced by cellular senescence and age-related stress, such as 
metabolic stress, may exceed the capacity limit of the phago-
cytic system of aged myeloid cells, resulting in the accumula-
tion of DAPMs and the activation of inflammasome.51,52 This 
process can be further intensified as aging is associated with 
decreases in autophagy.53 Autophagy is a cellular housekeep-
ing mechanism responsible for the removal of dysfunctional 
and damaged intracellular proteins via lysosomal degradation. 
Thus, one of the roles of autophagy is to prevent the activation 
of inflammasomes. The consequence of a decline in autopha-
gy with aging is therefore increased activation of the inflam-
masome and greater proinflammatory responses.54 All these 
abovementioned age-related changes can contribute to in-
flammaging among older adults. 
COPD AND INFLAMMAGING
Given that inflammaging in the context of immunosenescence 
has been implicated in the pathogenesis of most age-related 
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chronic diseases, COPD could be one of the target diseases of 
inflammaging.43,44 Previous study demonstrated that aged 
mice developed more inflammation leading to emphysema 
when exposed to cigarette smoke, compared to younger mice.55 
If inflammaging plays a significant role in the generation of 
COPD, the specific mechanisms for inflammaging-induced 
COPD need to be explored. Airway epithelial cells seem to be a 
key player in this regard. Airway epithelial cells are pivotal in-
nate immune cells and serve as a physical and molecular bar-
rier for particulate matter against microbes, as these cells en-
trap all dangerous molecules via mucociliary clearance, and 
then, these molecules ultimately get degraded in the gastroin-
testinal tract. By this process, airway epithelial cells can pre-
vent the access of molecules that can activate TLR deployed 
on their basolateral surface. Once TLR agonists breach this 
epithelial barrier, they become critical danger signals for acti-
vating the strategically arrayed cellular components of the in-
nate immune defense.56 The airway epithelial cells can serve 
as a physical and molecular barrier as they are polarized and 
maintain a tight junction that prevents paracellular transport 
of microbes and harmful substances into underlying lung tis-
sues in normal conditions. Aging is associated with decreased 
epithelial barrier function,57 abnormalities in both cilia struc-
ture and function,58 and reduced production of antimicrobial 
and anti-inflammatory peptides produced by epithelial cells, 
including secretory leukocyte protease inhibitor (SLPI).59 Not 
surprisingly, both alveolar and airway epithelial cells of smok-
ers with COPD reportedly have increased numbers of senes-
cent cells relative to healthy controls.60 Another key cell in terms 
of the generation of inflammaging in the lungs might be the 
airway and alveolar macrophages. Communication between 
airway epithelial cells and airway macrophages seems to be 
critical for immune homeostasis within the lungs. For instance, 
airway epithelial cells and airway macrophage cooperate to 
phagocytose particulates or microorganisms.61 Aging macro-
phages undergo the functional decline in phagocytosis, che-
motaxis, ability to secrete inflammatory cytokine, antigen-pre-
senting capacity, and bactericidal ability.28–31 Therefore, the 
Immunoscecescense
Airway epithelial cells Macrophage Lymphocyte
•  ↓ Function of phagocytosis, 
chemotaxis
• Antigen presenting capacity, etc
•  ↓ T-cell mediated innate immunity
• Loss of naïve T & B cells
•  ↓ CD4/CD8
•  ↑ Th17/Treg leading to autoimmunity
Microbes
TLR and NLR activation
Inflammaging
↓ Autophagy
Free fatty acid from adipose tissue
Factors produced by SASP
Oxidative stress
Activation of inflammasome
PAMP DAMP
• Activation of SLPI
• Dysfunction of epithelial barrier
• Change in airway microbiome
Dying senescent cells
Fig. 2. Inflammaging: a new mechanism of age-related disease. Low-grade inflammation called inflammaging during the ageing process may contrib-
ute to the pathogenesis of most age-related diseases. SLPI, secretory leukocyte protease inhibitor; PAMP, pathogen-associated molecular pattern; 
DAMP, damage-associated molecular pattern; TLR, Toll-like receptor; NLR, NOD-like receptor; SASP, senescence-associated secretory phenotype. 
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capability to protect the lungs against inhaled particles or in-
fectious agents will be decreased with aging, resulting in more 
inflammation in the lungs. Recently, changes in the airway mi-
crobiome have been implicated in various lung diseases.62-65 
Due to difficulties in sampling the airways while preventing 
contamination by concurrent oropharyngeal microbes, under-
standing of the airway microbiome was initially not easy; how-
ever, a series of studies utilizing DNA sequencing approaches 
have demonstrated the microbiota of the lower airways. Fur-
ther, it is now clearly accepted that variations in bacterial abun-
dance, content, and structure occur in chronic inflammatory 
airway diseases, such as cystic fibrosis,62 COPD,63 and asthma.64,65 
This means that a particular microbiome may be characteris-
tic of certain airway pathology. Taken together, the interaction 
between the microbiome and the host immune system within 
the airway, as well as the consequent loss of immune function 
with age, may have implications for the onset and progression 
of various age-related chronic airway diseases.66 Additionally, 
increased oxidative stress has been strongly implicated in both 
COPD and aging lungs as determined by reactive oxygen spe-
cies levels, oxidized DNA, lipid peroxidation and nitric oxide 
levels.67,68 Certainly, this increased level of oxidative stress can 
contribute to the development of inflammaging. Other factors 
associated with inflammaging, which have been described 
earlier, including intrinsically abnormal senescent immune 
cells, accumulation of DAMPs from the dying senescent cells 
in the setting of decreased autophagy in aging cells, or SASP 
produced by senescent cells, can also contribute to the devel-
opment of inflammaging in the lungs of smokers, thus, possi-
bly, leading to COPD. As described above, aging lungs seem 
to be prone to developing inflammation in response to certain 
stimuli irrespective of whether they are related to inflammag-
ing or not. From the COPD standpoint, chronic inflammation 
can develop when inflammation-prone aging lungs are repeat-
edly exposed to respiratory irritants, such as cigarette smoke, 
ultimately leading to tissue destruction and the development of 
COPD. Notably, COPD patients often undergo acute exacer-
bation. In the cases of acute exacerbation of COPD, which is 
typically caused by a viral or bacterial infection, chronic inflam-
mation can be further intensified.69 Intriguingly, only 15% to 
20% of smokers develop clinically significant COPD. Thus, the 
majority of smokers do not develop COPD.70 This is different 
from the mouse model of emphysema, which gives a predict-
able dose-response relationship between smoking amount and 
emphysema.70 Currently, we do not know the reason behind 
only a small percentage of smokers developing COPD. If im-
munosenescence and/or inflammaging play a critical role in 
the development of COPD, the reasoning for COPD occurring 
in a small percentage of smokers can perhaps be explained 
from immunosenescence or inflammaging or both perspec-
tives. There is reportedly a huge inter-individual variation in 
inflammaging susceptibility, which seems to be, in part, genet-
ically determined through polymorphisms of promoter regions 
of cytokine genes or the length of telomeres.29 A negative cor-
relation between telomere length and the levels of C-reactive 
protein71 and IL-672 has also been observed, and shorter telo-
mere length in leukocytes from COPD patients has been dem-
onstrated.73 In addition, enhanced telomere erosion has been 
observed in the small airway epithelium from COPD patients.74 
Therefore, it is quite possible that susceptibility to inflammag-
ing, which is genetically determined, may explain the inter-in-
dividual vulnerability to the development of COPD among 
smokers. In addition, thymic involution, a factor associated with 
immunosenescence, begins early in life, and the size of the na-
ïve cell pool is mostly determined before puberty.33 Thus, it is 
possible that immunosenescence is significantly affected by 
the history of an individual’s exposure to pathogens. In other 
words, the cumulative effects of antigenic stressors may deter-
mine immunosenescence or inflammaging or both and thus 
explain the differences among smokers in their susceptibility 
to the development of COPD (Fig. 2). 
CONCLUSION
Based on our literature review, we have proposed immunose-
nescence and inflammaging as the driving mechanisms of the 
development of COPD and have outlined why only a minority 
of smokers develop COPD (Fig. 3). If this is true, we could slow 
the progression of COPD by regulating immunosenescence 
and inflammaging in the lungs. Future studies will be needed 
to support our hypotheses.
Repeated exposure to 
noxious particles or gases
Chronic airway inflammation
Aging & immunosenescence
Different levels of inflammaging
Some smokers develop COPD
Suboptimal 
lung growth
Individual exposure 
history to pathogen
Genetic 
susceptibility
Fig. 3. Overview of immune hypotheses on COPD. Different levels of in-
flammaging caused by immunosenescence determine the susceptibility 
of individuals to COPD. COPD, chronic obstructive pulmonary disease. 
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